PharmExec Blog

UBS Life Science Conference Dominated by Wall Street Drama

The UBS meeting’s annual Global Life Sciences Conference this week in Manhattan confronted a unique nexus of Wall Street’s manic behaviors resulting from the nation’s financial crisis and the heavy presence of security on the streets and at the conference hotel as the Sept. 22-25 meeting coincides with nearby UN sessions. These events heightened the pre-existing concerns among health care investors and company executives about the closed IPO window, lack of VC funding for start ups and emerging companies and credit crunch. There was a “Black Monday” mood of resignation and humor heard among the attendees as they shared their reactions to the unfolding Wall Street and governmental drama that seemed impossible not long ago.

UBS publicized an anticipated attendance of 3,000 investors which may be difficult to produce with attention easily diverted by the market swings and lack of appetite to invest. Attendance Monday was sparse in the morning with an increase peaking with a standing- room-only attendance at the 2:00 pm Pfizer presentation. The audience listened intently looking for some favorable news from this industry giant. Ian Read, President of Pfizer’s Worldwide Pharmaceutical Operations, gave a reassuring talk that Pfizer was doing its best to remain strong and produce the future revenues worldwide that stockholders depend upon. But then when the Dow indicator reached a 370 point loss and the price of oil at $120 per barrel (the largest one-day price increase in history) appeared on the MS NBC financial news screen in the major hall outside the presentation rooms, the attendance returned to low morning levels.

It wasn’t surprising that expectations were low as attendees went through the motions of listening in on some private and public companies talks that appealed to them or from whom they wanted to hear reassurance on their pre-existing investments. There wasn’t any of the excitement that marked meetings in previous years. In fact, the high drama of the day was the Hoffman La Roche, Ltd presentation in the morning. Curiosity about the implementation plans for Roche’s buyout of the remaining 40% of Genentech and Roche’s access to sufficient funds dominated the questions in the packed Roche breakout session. The audience seemed sadly resigned to the outcome anticipated by the Roche speakers Dr. Jean-Jacques Garaud, Chief Medical Officer & Head of Global Drug Development, and Dr. Karl Mahler, Head of Investor Relations. Genentech presents at the conference on Wednesday.

This week’s four-day conference includes over 300 companies in biotechnology, genomics and discovery tool, medical technology and pharmaceutical fields. It has been one the largest annual life science investment meetings on the East Coast rivaling that of JP Morgan’s (former “H&Q’s” January meeting in San Francisco.

This entry was posted in Deals and tagged , , . Bookmark the permalink. Post a comment or leave a trackback: Trackback URL.


  1. Ex-Pfizer
    Posted September 24, 2008 at 8:33 am | Permalink

    Ian Read presented a shell game. There is no pipeline or strategy at Pfizer, just a bunch of mumbo jumbo about rehashing old products with no commercial value. A total joke. Reassuring?????

  2. Robin Lipschitz, MD
    Posted October 2, 2009 at 1:00 pm | Permalink

    What was the overall response to Angioblast regarding their pipeline cardiac regenerative product?
    Looks like Mesoblast (on Australian stock exchange and controls)1/3 Angio.) should have benefitted greatly but seems to be lagging despite good preliminary data on their cardiac and musculoskeletal fronts.

One Trackback

  1. [...] ago.”You can read more at in the article entitled “UBS Life Science Conference Dominated by Wall Street Drama“. I also commented on the Roche breakout sessions when attendees have the opportunities to [...]

Post a Comment

Your email is never published nor shared. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

  • Categories

  • Meta